Published in Science on December 05, 2003
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron (2010) 4.76
Misfolded proteins partition between two distinct quality control compartments. Nature (2008) 4.75
Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet (2009) 3.59
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast (2007) 3.30
Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet (2009) 3.06
The life of lipid droplets. Biochim Biophys Acta (2008) 2.75
Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein. Neuron (2014) 2.69
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (2013) 2.61
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci U S A (2004) 2.33
Effects of Q/N-rich, polyQ, and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitro. Proc Natl Acad Sci U S A (2004) 2.27
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A (2011) 2.15
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J (2009) 2.09
Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem (2011) 1.96
A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol (2011) 1.95
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem (2008) 1.94
A chaperone pathway in protein disaggregation. Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104. J Biol Chem (2005) 1.92
Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science (2013) 1.85
Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A (2011) 1.85
alpha-Synuclein and neuronal cell death. Mol Neurodegener (2009) 1.85
Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev (2008) 1.81
A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci (2010) 1.80
Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A (2010) 1.73
Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J Biol Chem (2010) 1.69
Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet (2013) 1.63
The function of α-synuclein. Neuron (2013) 1.63
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta (2008) 1.51
Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell (2008) 1.48
Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol (2006) 1.47
Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci (2005) 1.41
α-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. J Cell Biol (2011) 1.41
RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion (2011) 1.40
shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity. PLoS Genet (2016) 1.40
Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest (2008) 1.38
Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet (2008) 1.37
Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun (2006) 1.32
α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci (2012) 1.27
Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis (2012) 1.25
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem (2008) 1.24
Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol (2009) 1.19
α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci (2011) 1.16
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Lipid droplets and peroxisomes: key players in cellular lipid homeostasis or a matter of fat--store 'em up or burn 'em down. Genetics (2013) 1.13
Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell (2014) 1.13
α-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J Biol Chem (2013) 1.12
Genetic and environmental factors influencing glutathione homeostasis in Saccharomyces cerevisiae. Mol Biol Cell (2004) 1.12
An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol (2007) 1.10
The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci (2014) 1.10
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Chem Rev (2014) 1.10
Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics (2005) 1.09
Profilin 1 associates with stress granules and ALS-linked mutations alter stress granule dynamics. J Neurosci (2014) 1.09
Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res (2009) 1.08
Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding. J Am Chem Soc (2011) 1.08
Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol (2007) 1.08
Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. J Biol Chem (2009) 1.08
The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol (2009) 1.08
Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. J Biol Chem (2012) 1.07
Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein Cell (2011) 1.07
Expanding roles for lipid droplets. Curr Biol (2015) 1.06
Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem (2011) 1.04
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain (2014) 1.03
Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis. Cold Spring Harb Perspect Biol (2011) 1.02
Yeast toxicogenomics: genome-wide responses to chemical stresses with impact in environmental health, pharmacology, and biotechnology. Front Genet (2012) 1.02
Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol (2011) 1.01
Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms. EMBO Mol Med (2009) 1.00
Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism. Biochemistry (2006) 1.00
Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol (2014) 0.99
Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. BMC Biol (2006) 0.97
Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis. J Mol Neurosci (2010) 0.96
Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet (2014) 0.96
Engineering enhanced protein disaggregases for neurodegenerative disease. Prion (2015) 0.96
Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J Neuroinflammation (2011) 0.95
Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Mol Psychiatry (2012) 0.95
Protein aggregation and polyasparagine-mediated cellular toxicity in Saccharomyces cerevisiae. Prion (2007) 0.95
The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet (2014) 0.95
α-Synuclein oligomers with broken helical conformation form lipoprotein nanoparticles. J Biol Chem (2013) 0.95
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
Novel suppressors of alpha-synuclein toxicity identified using yeast. Hum Mol Genet (2008) 0.94
An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brain. Front Physiol (2012) 0.93
The role of the Parkinson's disease gene PARK9 in essential cellular pathways and the manganese homeostasis network in yeast. PLoS One (2012) 0.93
Clearance and phosphorylation of alpha-synuclein are inhibited in methionine sulfoxide reductase a null yeast cells. J Mol Neurosci (2009) 0.93
Enhancing protein disaggregation restores proteasome activity in aged cells. Aging (Albany NY) (2013) 0.92
Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. J Biol Chem (2011) 0.91
Expression of Human CTP synthetase in Saccharomyces cerevisiae reveals phosphorylation by protein kinase A. J Biol Chem (2005) 0.91
Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum Mol Genet (2011) 0.91
Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. Dis Model Mech (2014) 0.91
NAD+ salvage pathway proteins suppress proteotoxicity in yeast models of neurodegeneration by promoting the clearance of misfolded/oligomerized proteins. Hum Mol Genet (2013) 0.91
TDP-43 toxicity in yeast. Methods (2010) 0.91
α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. Proc Natl Acad Sci U S A (2012) 0.91
The impact of genetic research on our understanding of Parkinson's disease. Prog Brain Res (2010) 0.90
Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet (2014) 0.90
Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease. Mol Cell Proteomics (2008) 0.88
The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models. Cell Death Differ (2012) 0.87
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Impairment of the ubiquitin-proteasome system by protein aggregation. Science (2001) 11.51
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
An essential role for a phospholipid transfer protein in yeast Golgi function. Nature (1990) 4.63
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
Basic Medical Research Award. The ubiquitin system. Nat Med (2000) 4.03
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell (2002) 3.21
Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci (2001) 3.10
A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol (2003) 2.97
Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science (2003) 2.89
alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem (2000) 2.60
Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem (2001) 2.49
The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron (2003) 2.43
alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A (2001) 1.80
Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry (1998) 1.80
Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience (2001) 1.80
Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron (2002) 1.78
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol (2003) 1.67
Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci (2000) 1.63
A role for phospholipase D (Pld1p) in growth, secretion, and regulation of membrane lipid synthesis in yeast. J Biol Chem (1998) 1.61
Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest (2003) 1.52
Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J Mol Biol (2002) 1.52
Genetics of Parkinson's disease. J Neurol (2001) 1.47
Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev (2003) 1.41
SPO14 separation-of-function mutations define unique roles for phospholipase D in secretion and cellular differentiation in Saccharomyces cerevisiae. Genetics (2001) 1.22
Hsp90 as a capacitor of phenotypic variation. Nature (2002) 8.90
Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell (2007) 8.84
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 7.16
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell (2009) 6.20
Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science (2005) 5.04
Increase in activity during calorie restriction requires Sirt1. Science (2005) 4.90
A neuronal isoform of the aplysia CPEB has prion-like properties. Cell (2003) 4.16
Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science (2004) 4.01
Prions as adaptive conduits of memory and inheritance. Nat Rev Genet (2005) 3.97
Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet (2009) 3.59
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell (2012) 3.44
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast (2007) 3.30
Cryptic variation in morphological evolution: HSP90 as a capacitor for loss of eyes in cavefish. Science (2013) 3.15
Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet (2009) 3.06
Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science (2002) 3.05
HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell (2012) 2.94
α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol (2010) 2.93
Prions are a common mechanism for phenotypic inheritance in wild yeasts. Nature (2012) 2.89
Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science (2013) 2.79
Hsp90 and environmental stress transform the adaptive value of natural genetic variation. Science (2010) 2.68
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
A natively unfolded yeast prion monomer adopts an ensemble of collapsed and rapidly fluctuating structures. Proc Natl Acad Sci U S A (2007) 2.62
Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (2013) 2.61
Prion switching in response to environmental stress. PLoS Biol (2008) 2.61
Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A (2006) 2.59
Prion recognition elements govern nucleation, strain specificity and species barriers. Nature (2007) 2.57
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A (2009) 2.35
Prions as protein-based genetic elements. Annu Rev Microbiol (2002) 2.21
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell (2006) 2.14
Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell (2006) 2.09
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A (2011) 2.03
Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays (2004) 2.02
Retracted SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci (2012) 2.00
Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science (2002) 1.99
The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. Proc Natl Acad Sci U S A (2007) 1.99
A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol (2011) 1.95
Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal. Proc Natl Acad Sci U S A (2006) 1.92
Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets (2009) 1.91
Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol (2013) 1.88
Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. Annu Rev Genet (2010) 1.88
Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci U S A (2008) 1.88
HSP90 affects the expression of genetic variation and developmental stability in quantitative traits. Proc Natl Acad Sci U S A (2008) 1.87
Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science (2013) 1.85
Widespread regulation of translation by elongation pausing in heat shock. Mol Cell (2013) 1.85
A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A (2006) 1.85
Epigenetics in the extreme: prions and the inheritance of environmentally acquired traits. Science (2010) 1.84
Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. EMBO J (2008) 1.82
Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev (2008) 1.81
The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J (2011) 1.80
Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat Struct Mol Biol (2007) 1.77
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet (2006) 1.77
Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci U S A (2006) 1.76
Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A (2010) 1.73
Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol (2010) 1.63
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A (2004) 1.62
An intrinsically disordered yeast prion arrests the cell cycle by sequestering a spindle pole body component. J Cell Biol (2012) 1.60
Blessings in disguise: biological benefits of prion-like mechanisms. Trends Cell Biol (2013) 1.56
Atypical AAA+ subunit packing creates an expanded cavity for disaggregation by the protein-remodeling factor Hsp104. Cell (2007) 1.56
The prion protein knockout mouse: a phenotype under challenge. Prion (2007) 1.51
Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J Vis Exp (2008) 1.50
Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron (2009) 1.49
Opposing effects of glutamine and asparagine govern prion formation by intrinsically disordered proteins. Mol Cell (2011) 1.49
Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? Nat Rev Neurosci (2010) 1.46
Mechanisms of protein-folding diseases at a glance. Dis Model Mech (2014) 1.45
HSP90-buffered genetic variation is common in Arabidopsis thaliana. Proc Natl Acad Sci U S A (2008) 1.45
Prion induction involves an ancient system for the sequestration of aggregated proteins and heritable changes in prion fragmentation. Proc Natl Acad Sci U S A (2010) 1.43
A heritable switch in carbon source utilization driven by an unusual yeast prion. Genes Dev (2009) 1.43
Prion protein gene polymorphisms in Saccharomyces cerevisiae. Mol Microbiol (2003) 1.41
Mapping differential interactomes by affinity purification coupled with data-independent mass spectrometry acquisition. Nat Methods (2013) 1.41
Phenotypic diversity and altered environmental plasticity in Arabidopsis thaliana with reduced Hsp90 levels. PLoS One (2007) 1.39
Heritable remodeling of yeast multicellularity by an environmentally responsive prion. Cell (2013) 1.38
Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest (2008) 1.38
Unraveling infectious structures, strain variants and species barriers for the yeast prion [PSI+]. Nat Struct Mol Biol (2009) 1.35
Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol (2013) 1.33
Motor mechanism for protein threading through Hsp104. Mol Cell (2009) 1.33
Transgenerational epigenetic inheritance: how important is it? Nat Rev Genet (2013) 1.32
Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol (2011) 1.31
Dominant gain-of-function mutations in Hsp104p reveal crucial roles for the middle region. Mol Biol Cell (2004) 1.29
ResponseNet: revealing signaling and regulatory networks linking genetic and transcriptomic screening data. Nucleic Acids Res (2011) 1.28
Hsp110 chaperones regulate prion formation and propagation in S. cerevisiae by two discrete activities. PLoS One (2008) 1.26
Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest (2012) 1.25
Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J Neurosci (2009) 1.24
Heat shock factor 1 regulates lifespan as distinct from disease onset in prion disease. Proc Natl Acad Sci U S A (2008) 1.20
Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol (2009) 1.19
Amyloid deposits: protection against toxic protein species? Cell Cycle (2009) 1.18
Diminishing apoptosis by deletion of Bax or overexpression of Bcl-2 does not protect against infectious prion toxicity in vivo. J Neurosci (2007) 1.15
Lymphotoxin-dependent prion replication in inflammatory stromal cells of granulomas. Immunity (2008) 1.14
Plasmodium falciparum heat shock protein 110 stabilizes the asparagine repeat-rich parasite proteome during malarial fevers. Nat Commun (2012) 1.12
Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. Proc Natl Acad Sci U S A (2008) 1.06
Protein-only mechanism induces self-perpetuating changes in the activity of neuronal Aplysia cytoplasmic polyadenylation element binding protein (CPEB). Proc Natl Acad Sci U S A (2011) 1.06
Conversion of a yeast prion protein to an infectious form in bacteria. Proc Natl Acad Sci U S A (2010) 1.06
The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration. Exp Gerontol (2008) 1.04
Optical trapping with high forces reveals unexpected behaviors of prion fibrils. Nat Struct Mol Biol (2010) 1.04
Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem (2011) 1.04
Prion formation by a yeast GLFG nucleoporin. Prion (2012) 1.04